Correction to: Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study (Advances in Therapy, (2021), 38, 7, (3724-3742), 10.1007/s12325-021-01722-w)

Jai Perumal*, Roumen Balabanov, Ray Su, Roger Chang, Laura Balcer, Steven Galetta, Denise I. Campagnolo, Robin Avila, Lily Lee, Danette Rutledge, Robert J. Fox

*Corresponding author for this work

Research output: Contribution to journalComment/debatepeer-review

Abstract

A correction to this paper has been published: https://doi.org/10.1007/s12325-021-01815-6.

Original languageEnglish (US)
Pages (from-to)3743-3744
Number of pages2
JournalAdvances in Therapy
Volume38
Issue number7
DOIs
StatePublished - Jul 2021

ASJC Scopus subject areas

  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Correction to: Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study (Advances in Therapy, (2021), 38, 7, (3724-3742), 10.1007/s12325-021-01722-w)'. Together they form a unique fingerprint.

Cite this